Stockreport

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

BiomX Inc. COmmon Stock  (PHGE) 
PDF Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial  BiomX co [Read more]